|
Report Date : |
15.10.2014 |
IDENTIFICATION DETAILS
|
Name : |
GENOMICS BIOSCIENCE & TECHNOLOGY CO., LTD. |
|
|
|
|
Registered Office : |
14F., No.100, Sec. 1, Sintai 5th Rd., Xizhi Dist., New Taipei City 22102, |
|
|
|
|
Country : |
Taiwan |
|
|
|
|
Financials (as on) : |
30.06.2013 |
|
|
|
|
Date of Incorporation : |
16.10.2001 |
|
|
|
|
Com. Reg. No.: |
12953452 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturing and sale
of chemical products and providing related analysis services |
|
|
|
|
No. of Employees : |
100 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Slow |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 1, 2014
|
Country Name |
Previous Rating (31.03.2014) |
Current Rating (01.06.2014) |
|
Taiwan |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
TAIWAN - ECONOMIC OVERVIEW
Taiwan has a dynamic capitalist
economy with gradually decreasing government guidance of investment and foreign
trade. Exports, led by electronics, machinery, and petrochemicals have provided
the primary impetus for economic development. This heavy dependence on exports
exposes the economy to fluctuations in world demand. Taiwan's diplomatic
isolation, low birth rate, and rapidly aging population are other major
long-term challenges. Free trade agreements have proliferated in East Asia over
the past several years, and following the landmark Economic Cooperation
Framework Agreement (ECFA) signed with China in June 2010, Taiwan in July 2013
signed a free trade deal with New Zealand—Taipei’s first-ever with a country
with which it does not maintain diplomatic relations—and in November inked a
trade pact with Singapore. Negotiations continue on follow-on components of
ECFA regarding trade in goods and a dispute resolution mechanism; a trade in
services agreement is under review in the legislature. Taiwan's Total Fertility
rate of just over one child per woman is among the lowest in the world, raising
the prospect of future labor shortages, falling domestic demand, and declining
tax revenues. Taiwan's population is aging quickly, with the number of people
over 65 accounting for 11.2% of the island's total population as of 2012. The
island runs a large overall trade surplus largely because of its surplus with
China, and its foreign reserves are the world's sixth largest, behind China,
Japan, Saudi Arabia, Russia, and Switzerland. In 2006 China overtook the US to
become Taiwan's second-largest source of imports after Japan. China is also the
island's number one destination for foreign direct investment. Taiwan since
2009 has gradually loosened rules governing Chinese investment on the island,
and has also secured greater market access for its investors in the mainland.
In August 2012, Taiwan Central Bank signed a memorandum of understanding on
cross-Strait currency settlement with its Chinese counterpart. The MOU allows
for the direct settlement of Chinese RMB and the New Taiwan dollar across the
Strait, which could help develop Taiwan into a local RMB hub. Closer economic
links with the mainland bring greater opportunities for the Taiwan economy, but
also poses new challenges as the island becomes more economically dependent on
China while political differences remain unresolved
|
Source
: CIA |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
14F., No.100, Sec. 1, Sintai 5th Rd., Xizhi Dist., New Taipei City
22102, Taiwan (R.O.C.) |
|
Supplied Address: |
|
|
Telephone Number: |
+886-2-2696-1658 |
|
Fax Number: |
Notes: The exact name
and address are as above.
Subject
was incorporated on 2001-10-16 with registered number 12953452 as Joint Stock
Company in Taiwan.
Subject is listed on the Taiwan Stock Exchange on 2013-12-16.
Change of Name
|
Former Chinese Name: |
基龍米克斯生物科技有限公司 |
|
Current Chinese Name: |
基龍米克斯生物科技股份有限公司 |
Factory
|
Address: |
4F, No. 92, Sec. 1, Xintai Five Rd., Xizhi Dist., New Taipei City, Taiwan |
|
Date of Registration: |
2014-5-13 |
|
Factory Registration Number: |
65003092 |
|
Factory Manager: |
Zhuoyuan You |
|
Status: |
In Production |
|
Date of Last
Annual Return: |
2014-5-13 |
|
Major Products: |
199 Other Chemical Products |
|
Name |
Subscription Shares |
|
Zhuoyuan You |
|
|
1,521,000 |
|
|
Mengxian Zhou |
1,170,000 |
|
Zhaoxi Huang |
865,000 |
|
Junqi Jiang |
638,000 |
|
Huie Chen |
533,000 |
|
Liyuan Huang |
304,000 |
|
Dingyuan You |
900,000 |
|
Yingzi Lin |
200,000 |
|
He Shi |
181,000 |
|
Wenzhi Liao |
200,000 |
Core Management
Directors
|
1 |
||
|
Name |
Zhuoyuan You |
|
|
Position |
Chairman of the Board |
|
|
2 |
||
|
Name |
Mengxian Zhou |
|
|
Position |
Vice Chairman of the Board |
|
|
3 |
||
|
Name |
Zhaoxi Huang |
|
|
Position |
Director |
|
|
4 |
||
|
Name |
Junqi Jiang |
|
|
Position |
Director |
|
|
5 |
||
|
Name |
Huie Chen |
|
|
Position |
Director |
|
|
6 |
||
|
Name |
Liyuan Huang |
|
|
Position |
Director |
|
|
7 |
||
|
Name |
Dingyuan You |
|
|
Position |
Director |
|
|
8 |
||
|
Name |
Yixiong Zeng |
|
|
Position |
Independent Director |
|
|
9 |
||
|
Name |
Pengjin Tang |
|
|
Position |
Independent Director |
|
|
10 |
||
|
Name |
Yingzi Lin |
|
|
Position |
Supervisor |
|
|
11 |
||
|
Name |
He Shi |
|
|
Position |
Supervisor |
|
|
12 |
||
|
Name |
Wenzhi Liao |
|
|
Position |
Supervisor |
|
Personnel Structure
|
Total Employees |
About 100 Employees |
Offices & Factories
|
|
Headquarters |
|
Add |
14F., No.100, Sec. 1, Sintai 5th Rd., Xizhi Dist., New Taipei City 22102, Taiwan (R.O.C.) |
Production Information
Subject is engaged in manufacturing of chemical products, etc.
Subject has a factory in Taiwan for production.
Purchase Information
The registered activities of subject:
|
Business Code |
Details |
|
C801010 |
Basic chemical industry |
|
C801030 |
Precision manufacturing chemical materials |
|
F107200 |
Chemical raw materials wholesaling |
|
F207200 |
Chemical raw materials retailing |
|
IC01010 |
The drug inspection industry |
|
IG01010 |
Biological technology services |
|
F401010 |
The international trade |
|
CE01010 |
General instrument manufacturing |
|
F107070 |
Veterinary drug wholesaling |
|
F108040 |
Cosmetics wholesaling |
|
F121010 |
Food additives wholesaling |
|
F207070 |
Animal drug retailing |
|
F208040 |
Cosmetics retailing |
|
F221010 |
Food additives retailing |
|
F113030 |
Precision instruments wholesaling |
|
F113050 |
Computer and transactional machine equipment wholesaling |
|
F118010 |
Information software wholesaling |
|
F213030 |
Computers and transactional machinery and equipment retailing |
|
F213040 |
Precision instruments retailing |
|
F218010 |
Information software retailing |
|
I301010 |
Information software services |
|
I301020 |
Data processing services |
|
I301030 |
Electronic information supply services |
|
IZ99990 |
Other business services |
|
EZ05010 |
Instrumentation installation engineering |
|
ZZ99999 |
Besides licensed business, all other business items those are not banned or restricted. |
|
F108031 |
Medical equipment wholesaling |
|
F208031 |
Medical equipment retailing |
The raw materials for production are both purchased at home and abroad.
Subject is engaged in sale of chemical products, etc.
The major products of the subject are chemical products related to oligonucleotide synthesis, gene synthesis, gene cloning, custom peptide synthesis and so on.
Subject also provides the analysis services of genosome, transcriptome, next generation sequencing, proteomics, metabolomics, cellular, software, etc.
Subject’s sales regions domestic market, Japan, Singapore, USA, Europe, etc.
Import and export right:
|
Import right |
Yes |
|
Export right |
Yes |
Purchase
Domestic Purchase
|
Products |
Raw materials,
etc. |
|
Payment Terms |
T/T, Cash, etc. |
Import
|
Products |
Raw materials,
etc. |
|
Payment Terms |
L/C, T/T, etc. |
Domestic Markets
|
Product |
Chemical products, etc. |
|
Selling Terms |
T/T, Cash, etc. |
Export
|
Product |
Chemical products, etc. |
|
Selling Terms |
L/C, T/T, etc. |
Unit: NTD/000
|
|
2013-6-30 |
2012-6-30 |
|
Cash and cash equivalents |
110,358.00 |
53,459.00 |
|
Notes receivable - net |
28,695.00 |
8,497.00 |
|
Accounts receivable - net |
94,743.00 |
30,515.00 |
|
Other accounts receivable |
11,147.00 |
4.00 |
|
Other accounts receivable-related parties |
1,215.00 |
0.00 |
|
Inventories |
46,191.00 |
38,023.00 |
|
Prepayment |
11,644.00 |
11,218.00 |
|
Other current assets |
1,365.00 |
8,532.00 |
|
Current assets |
305,358.00 |
150,248.00 |
|
Financial asset valued by cost-non current |
14,000.00 |
0.00 |
|
Equity method long term investment |
29,353.00 |
0.00 |
|
Long term investment prepayment |
1,446.00 |
0.00 |
|
Investment |
30,799.00 |
0.00 |
|
Other financial asset-non current |
3,800.00 |
0.00 |
|
Funds and investments |
48,599.00 |
0.00 |
|
Land |
59,937.00 |
22,343.00 |
|
Buildings and structures |
75,107.00 |
53,408.00 |
|
Machinery and equipment |
73,782.00 |
64,568.00 |
|
Transportation equipment |
253.00 |
309.00 |
|
Other equipment |
8,255.00 |
6,607.00 |
|
Fixed asset cost total |
217,334.00 |
147,235.00 |
|
Accumulated depreciation |
-17,916.00 |
-20,617.00 |
|
Construction in process and prepayment for equipment |
0.00 |
20,070.00 |
|
Fixed assets-net |
199,418.00 |
146,688.00 |
|
Business reputation |
2,207.00 |
0.00 |
|
Total intangible assets |
2,207.00 |
0.00 |
|
Refundable deposits |
2,233.00 |
8,752.00 |
|
Deferred expense |
9,000.00 |
8,442.00 |
|
Deferred income tax assets - non current |
90.00 |
551.00 |
|
Other assets |
11,323.00 |
17,745.00 |
|
Assets |
566,905.00 (USD 18,651,174.50) |
314,681.00 (USD 10,353,004.90) |
|
Short-term borrowing |
5,000.00 |
8,150.00 |
|
Notes Payable |
1,330.00 |
9,625.00 |
|
Accounts payable |
13,133.00 |
8,238.00 |
|
Expense payable |
15,264.00 |
9,025.00 |
|
Other accounts payable |
20,282.00 |
271.00 |
|
Account received in advance |
9,969.00 |
0.00 |
|
Long term Liabilities within one year and one operating cycle |
7,324.00 |
9,304.00 |
|
Other current liabilities |
1,169.00 |
6,024.00 |
|
Current liabilities |
73,471.00 |
50,637.00 |
|
Long-term borrowings |
105,103.00 |
64,838.00 |
|
Long-term liabilities |
105,103.00 |
64,838.00 |
|
Liabilities |
178,574.00 |
115,475.00 |
|
Common stock |
385,800.00 |
218,000.00 |
|
Capital reserves-share premium account |
32,332.00 |
21,939.00 |
|
Capital surplus- employee stock options |
660.00 |
158.00 |
|
Capital surplus |
32,992.00 |
22,097.00 |
|
Inappropriate retained earnings |
-30,873.00 |
-40,891.00 |
|
Retained earnings |
-30,873.00 |
-40,891.00 |
|
Cumulative translation adjustments |
412.00 |
0.00 |
|
Stockholders‘ equity and other adjustment |
412.00 |
0.00 |
|
Stockholders‘ equity |
388,331.00 (USD 12,776,089.90) |
199,206.00 (USD 6,553,877.40) |
|
Number of treasury stock acquired by the company and subsidiaries (unit: share) |
0.00 |
0.00 |
(As of 2014.10, 1 NTD = 0.0329 USD)
Unit: NTD/000
|
|
2013-1-1~2013-6-30 |
2012-1-1~2012-6-30 |
|
Sales |
52,889.00 (USD 1,740,048.10) |
37,331.00 (USD 1,228,189.90) |
|
Sales net |
52,889.00 |
37,331.00 |
|
Service income |
61,925.00 |
0.00 |
|
Operating income |
114,814.00 |
37,331.00 |
|
Sales cost |
47,072.00 |
38,512.00 |
|
Labor cost |
47,088.00 |
0.00 |
|
Labor cost total |
47,088.00 |
0.00 |
|
Operating cost total |
94,160.00 |
38,512.00 |
|
Operating margin (gross loss) |
20,654.00 |
-1,181.00 |
|
Sale expenses |
24,469.00 |
21,434.00 |
|
General and administrative expenses |
16,076.00 |
14,009.00 |
|
Research and development expenses |
6,374.00 |
3,779.00 |
|
Operating expenses |
46,919.00 |
39,222.00 |
|
Operating income (loss)-net |
-26,265.00 |
-40,403.00 |
|
Interest income |
394.00 |
80.00 |
|
Exchange interest |
272.00 |
27.00 |
|
Miscellaneous income |
1,218.00 |
728.00 |
|
Non-operating revenues and gains |
1,884.00 |
835.00 |
|
Interest expense |
1,294.00 |
1,323.00 |
|
Investment loss by the equity method |
531.00 |
0.00 |
|
Investment loss |
531.00 |
0.00 |
|
Fixed assets loss |
624.00 |
0.00 |
|
Miscellaneous expense |
6.00 |
0.00 |
|
Non-operating expenses and losses |
2,455.00 |
1,323.00 |
|
Net pre-tax profit (loss) of continue to business units |
-26,836.00 |
-40,891.00 |
|
Income tax expense (benefit) |
4,037.00 |
0.00 |
|
Net interest (loss) from continuing operations |
-30,873.00 |
-40,891.00 |
|
Net income (loss) |
-30,873.00 |
-40,891.00 |
|
Net interest (loss) from continuing operations |
-0.80 |
-2.88 |
|
Primary Earnings per Share |
-0.80 |
-2.88 |
(As of 2014.10, 1 NTD = 0.0329 USD)
Unit: NTD/000
|
|
2013-1-1~2013-6-30 |
2012-1-1~2012-6-30 |
|
Cash Flows from Operating Activities - Indirect Method |
|
|
|
Net Income (Loss) |
-30,873.00 |
-40,891.00 |
|
Adjustments to Reconcile Net Income to Net Cash Provided by (Used in) Operating Activities |
|
|
|
4,883.00 |
3,303.00 |
|
|
2,151.00 |
1,805.00 |
|
|
Share-based Compensation |
185.00 |
158.00 |
|
Investment Loss (Income) Recognized under Equity Method) |
531.00 |
0.00 |
|
Loss (Gain) on Disposal of Property, Plan and Equipment |
624.00 |
0.00 |
|
Changes in Operating Assets and Liabilities |
|
|
|
-28,584.00 |
-8,152.00 |
|
|
27,407.00 |
24,516.00 |
|
|
Decrease (Increase) in Accounts Receivable - Related Parties |
0.00 |
0.00 |
|
24,220.00 |
-4.00 |
|
|
-1,215.00 |
0.00 |
|
|
Decrease (Increase) in Inventories |
-280.00 |
3,303.00 |
|
Decrease (Increase) in prepayment |
-4,782.00 |
-1,024.00 |
|
Decrease (Increase) in Other Current Assets |
-284.00 |
-2,899.00 |
|
Decrease (Increase) in deferred tax assets |
4,037.00 |
0.00 |
|
Increase (Decrease) in Notes Payable |
-170.00 |
8,857.00 |
|
Increase (Decrease) in Accounts Payable |
-3,779.00 |
2,384.00 |
|
Increase (Decrease) in Accrued Expenses |
-3,246.00 |
-3,070.00 |
|
Increase (Decrease) in Other payables |
-14,007.00 |
-978.00 |
|
Increase (Decrease) in advance receipt |
1,957.00 |
0.00 |
|
Increase (Decrease) in Other Current Liabilities |
-665.00 |
5,198.00 |
|
Net Cash Provided by (Used in) Operating Activities |
-21,890.00 |
-7,494.00 |
|
Cash Flows from Investing Activities |
|
|
|
Acquisition of Financial Assets Carried at Cost |
-14,000.00 |
0.00 |
|
Long term equity investment increased equity method |
-29,472.00 |
0.00 |
|
Increase (Decrease) in long-term investment fund in advance |
-1,446.00 |
0.00 |
|
Purchase of Property, Plant and Equipment |
-3,473.00 |
-29,412.00 |
|
Proceeds from Disposal of Property, Plant and Equipment |
13,857.00 |
0.00 |
|
Decrease (Increase) in Refundable Deposits |
54.00 |
-6,951.00 |
|
Increase in Deferred Charges |
-895.00 |
-1,016.00 |
|
Purchase of Intangible Assets |
0.00 |
0.00 |
|
Decrease (Increase) in other financial assets |
-800.00 |
0.00 |
|
Net Cash Provided by (Used in) Investing Activities |
-36,175.00 |
-37,379.00 |
|
Cash Flows from Financing Activities |
|
|
|
Decrease (Increase) in short term borrowings |
5,000.00 |
-30,966.00 |
|
Repayment for long-term borrowing |
-30,319.00 |
-4,537.00 |
|
Increment of cash |
0.00 |
120,000.00 |
|
Net Cash Provided by (Used in) Financing Activities |
-25,319.00 |
84,497.00 |
|
Net Increase (Decrease) in Cash and Cash Equivalents |
-83,384.00 |
39,624.00 |
|
Cash and Cash Equivalents, Beginning of year |
193,742.00 |
13,835.00 |
|
Cash and Cash Equivalents, End of year |
110,358.00 |
53,459.00 |
|
Supplemental Cash Flow Information |
|
|
|
Interest Paid |
885.00 |
1,539.00 |
|
Interest Paid- Excluding Capitalized Interest |
885.00 |
1,539.00 |
|
33.00 |
20.00 |
|
|
Investing Activities Not Affecting Both Cash and Non-cash Items |
|
|
|
Transferred inventories of fixed asset |
4,989.00 |
8,175.00 |
|
Cash dividends payable |
19,289.00 |
0.00 |
Note: We only obtain
the financial information above from official source for your reference.
Subject declined to disclose its bank details; from other source we could not obtain the relevant information, either.
Mortgage
|
1 |
|
|
Case Type: |
Chattel Mortgage |
|
File No.: |
100989 |
|
Debtor Name: |
Genomics
Bioscience & Technology Co., Ltd. |
|
Document Number: |
09930329190 |
|
Date of
Registration: |
2010-8-11 |
|
Date of
Alteration: |
2010-10-19 |
|
Status: |
-- |
|
2 |
|
|
Case Type: |
Chattel Mortgage |
|
File No.: |
100982 |
|
Debtor Name: |
Genomics
Bioscience & Technology Co., Ltd. |
|
Document Number: |
09930329200 |
|
Date of
Registration: |
2010-8-10 |
|
Status: |
-- |
Lawsuit
Up to date of reporting, no existing or latent litigation of the subject has been found.
Interview Details
|
Name |
Ms. Chen |
|
Department |
Sales Department |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.11 |
|
|
1 |
Rs.98.15 |
|
Euro |
1 |
Rs.77.68 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.